United Therapeutics Stock In The News
| UTHR Stock | USD 367.36 3.03 0.83% |
Our overall analysis of United Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards United Therapeutics. The specific impact of United Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of United Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using United Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out United Therapeutics Backtesting and United Therapeutics Hype Analysis. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.
United |
United Therapeutics Today Top News and Investor Outlook
United Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide United and other traded companies coverage with news coverage. We help investors stay connected with United headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on United Stock performance. Please note that trading solely based on the United Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
United Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the United earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about United Therapeutics that are available to investors today. That information is available publicly through United media outlets and privately through word of mouth or via United internal channels. However, regardless of the origin, that massive amount of United data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of United Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of United Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to United Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive United Therapeutics alpha.
United Largest EPS Surprises
Earnings surprises can significantly impact United Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2003-11-06 | 2003-09-30 | -0.04 | -0.03 | 0.01 | 25 | ||
2005-05-03 | 2005-03-31 | 0.14 | 0.16 | 0.02 | 14 | ||
2003-05-06 | 2003-03-31 | -0.09 | -0.07 | 0.02 | 22 | ||
2003-02-25 | 2002-12-31 | -0.08 | -0.06 | 0.02 | 25 | ||
2002-11-08 | 2002-09-30 | -0.16 | -0.14 | 0.02 | 12 | ||
2010-04-29 | 2010-03-31 | 0.29 | 0.32 | 0.03 | 10 |
United Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to United Therapeutics Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
20th of November 2024
Should You Invest in the Invesco Biotechnology Genome ETF at finance.yahoo.com
14th of November 2024
Acquisition by Michael Benkowitz of 2500 shares of United Therapeutics at 111.0 subject to... at gurufocus.com
13th of November 2024
Maryland Businesses Celebrate Expansions, Promotions and Milestones at finance.yahoo.com
11th of November 2024
Disposition of tradable shares by Michael Benkowitz of United Therapeutics at 412.2525 sub... at gurufocus.com
8th of November 2024
United Therapeutics president sells shares worth 9.97 million at investing.com
7th of November 2024
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Up... at finance.yahoo.com
6th of November 2024
United Therapeutics director Giltner sells shares worth 3.8 million at investing.com
5th of November 2024
United Therapeutics is a Top-Ranked Growth Stock Should You Buy at finance.yahoo.com
31st of October 2024
Electric Aircraft Startup Beta Raises 318 Million in New Round at finance.yahoo.com
24th of October 2024
Stewartville receives 1.1M business development public infrastructure grant at finance.yahoo.com
14th of October 2024
Disposition of 3400 shares by James Edgemond of United Therapeutics at 355.88 subject to R... at MacroaxisInsider
United Therapeutics Investors Sentiment
The influence of United Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in United. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
United Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for United Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average United Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on United Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards United Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, United Therapeutics' short interest history, or implied volatility extrapolated from United Therapeutics options trading.
Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.